Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Net Margin (2019 - 2025)

Revolution Medicines has reported Net Margin over the past 6 years, most recently at 2976.77% for Q4 2025.

  • Quarterly results put Net Margin at 2976.77% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 136301.33% (changed N/A YoY), and the annual figure for FY2023 was 3768.28%, down 306533.0%.
  • Net Margin for Q4 2025 was 2976.77% at Revolution Medicines, down from 2670.69% in the prior quarter.
  • Over the last five years, Net Margin for RVMD hit a ceiling of 2670.69% in Q3 2025 and a floor of 21770.49% in Q4 2023.
  • Median Net Margin over the past 4 years was 760.72% (2022), compared with a mean of 2757.55%.
  • Biggest five-year swings in Net Margin: soared 262334bps in 2022 and later plummeted -2139914bps in 2023.
  • Revolution Medicines' Net Margin stood at 556.83% in 2021, then surged by 33bps to 371.34% in 2022, then plummeted by -5763bps to 21770.49% in 2023, then surged by 86bps to 2976.77% in 2025.
  • The last three reported values for Net Margin were 2976.77% (Q4 2025), 2670.69% (Q3 2025), and 21770.49% (Q4 2023) per Business Quant data.